BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 33196851)

  • 1. Epigenome engineering: new technologies for precision medicine.
    Sgro A; Blancafort P
    Nucleic Acids Res; 2020 Dec; 48(22):12453-12482. PubMed ID: 33196851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR/Cas mediated epigenome editing for cancer therapy.
    Ansari I; Chaturvedi A; Chitkara D; Singh S
    Semin Cancer Biol; 2022 Aug; 83():570-583. PubMed ID: 33421620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stabilization of Foxp3 expression by CRISPR-dCas9-based epigenome editing in mouse primary T cells.
    Okada M; Kanamori M; Someya K; Nakatsukasa H; Yoshimura A
    Epigenetics Chromatin; 2017; 10():24. PubMed ID: 28503202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zinc Fingers, TALEs, and CRISPR Systems: A Comparison of Tools for Epigenome Editing.
    Waryah CB; Moses C; Arooj M; Blancafort P
    Methods Mol Biol; 2018; 1767():19-63. PubMed ID: 29524128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR/Cas-Based Epigenome Editing: Advances, Applications, and Clinical Utility.
    Goell JH; Hilton IB
    Trends Biotechnol; 2021 Jul; 39(7):678-691. PubMed ID: 33972106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Approaches to Epigenetic Therapies: From Drug Combinations to Epigenetic Editing.
    Majchrzak-Celińska A; Warych A; Szoszkiewicz M
    Genes (Basel); 2021 Jan; 12(2):. PubMed ID: 33572577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of heritable gene silencing for KRAB-dCas9 + DNMT3 and Ezh2-dCas9 + DNMT3 hit-and-run epigenome editing.
    O'Geen H; Tomkova M; Combs JA; Tilley EK; Segal DJ
    Nucleic Acids Res; 2022 Apr; 50(6):3239-3253. PubMed ID: 35234927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allele-Specific Epigenome Editing.
    Bashtrykov P; Jeltsch A
    Methods Mol Biol; 2018; 1767():137-146. PubMed ID: 29524132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR/Cas9 Epigenome Editing Potential for Rare Imprinting Diseases: A Review.
    Syding LA; Nickl P; Kasparek P; Sedlacek R
    Cells; 2020 Apr; 9(4):. PubMed ID: 32316223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editing the Epigenome: Reshaping the Genomic Landscape.
    Holtzman L; Gersbach CA
    Annu Rev Genomics Hum Genet; 2018 Aug; 19():43-71. PubMed ID: 29852072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR/Cas9-based epigenome editing: An overview of dCas9-based tools with special emphasis on off-target activity.
    Tadić V; Josipović G; Zoldoš V; Vojta A
    Methods; 2019 Jul; 164-165():109-119. PubMed ID: 31071448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic Editing in Prostate Cancer: Challenges and Opportunities.
    Pacheco MB; Camilo V; Henrique R; Jerónimo C
    Epigenetics; 2022 May; 17(5):564-588. PubMed ID: 34130596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenome editing for targeted DNA (de)methylation: a new perspective in modulating gene expression.
    Seem K; Kaur S; Kumar S; Mohapatra T
    Crit Rev Biochem Mol Biol; 2024; 59(1-2):69-98. PubMed ID: 38440883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic editing: Dissecting chromatin function in context.
    Policarpi C; Dabin J; Hackett JA
    Bioessays; 2021 May; 43(5):e2000316. PubMed ID: 33724509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A CRISPR-dCas Toolbox for Genetic Engineering and Synthetic Biology.
    Xu X; Qi LS
    J Mol Biol; 2019 Jan; 431(1):34-47. PubMed ID: 29958882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editing the Epigenome: Overview, Open Questions, and Directions of Future Development.
    Rots MG; Jeltsch A
    Methods Mol Biol; 2018; 1767():3-18. PubMed ID: 29524127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenome engineering in cancer: fairytale or a realistic path to the clinic?
    Falahi F; Sgro A; Blancafort P
    Front Oncol; 2015; 5():22. PubMed ID: 25705610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineering CRISPR mouse models of cancer.
    Weber J; Rad R
    Curr Opin Genet Dev; 2019 Feb; 54():88-96. PubMed ID: 31078083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR/Cas9-Based Engineering of the Epigenome.
    Pulecio J; Verma N; Mejía-Ramírez E; Huangfu D; Raya A
    Cell Stem Cell; 2017 Oct; 21(4):431-447. PubMed ID: 28985525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenome Editing in the Brain.
    Bashtrykov P; Jeltsch A
    Adv Exp Med Biol; 2017; 978():409-424. PubMed ID: 28523558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.